PHARMACYTE BIOTECH, INC.: 10-Q filed 2017-03-13

Name: PHARMACYTE BIOTECH, INC.: 10-Q filed 2017-03-13
Creator: PHARMACYTE BIOTECH, INC.

What PHARMACYTE BIOTECH, INC. reported in its quarterly report filed 2017-03-13 (fiscal Q3 2017): 29 published measures, 84 facts as tagged in accession 0001683168-17-000544.

This filing

Form: 10-Q (quarterly report)
Filed: 2017-03-13
Fiscal period: fiscal Q3 2017
Accession: 0001683168-17-000544 on SEC EDGAR

Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All PHARMACYTE BIOTECH, INC. filings.

Reported measures

Total assets

Resources recognized on the balance sheet. Book assets are not the market value of the business.

Period	Value	Unit	Days
At 2017-01-31	7,614,943	USD
At 2016-04-30	7,160,325	USD

Total liabilities

Recognized obligations at the reporting date. The definition and scope differ from interest-bearing debt.

Period	Value	Unit	Days
At 2017-01-31	578,267	USD
At 2016-04-30	637,639	USD

Stockholders equity

The reported residual interest after liabilities. It is an accounting amount, not market capitalization.

Period	Value	Unit	Days
At 2017-01-31	7,036,676	USD
At 2016-04-30	6,522,686	USD

Net income or loss

Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.

Period	Value	Unit	Days
2016-11-01 to 2017-01-31	-1,282,146	USD	92
2016-05-01 to 2017-01-31	-3,288,663	USD	276
2015-11-01 to 2016-01-31	-1,791,097	USD	92
2015-05-01 to 2016-01-31	-4,941,720	USD	276

Revenue

Revenue under this specific accounting concept. A missing value is not zero; filers can use other revenue concepts.

Period	Unit	Days
2016-11-01 to 2017-01-31	USD	92
2016-05-01 to 2017-01-31	USD	276
2015-11-01 to 2016-01-31	USD	92
2015-05-01 to 2016-01-31	USD	276

Retained earnings or deficit

Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.

Period	Value	Unit	Days
At 2017-01-31	-87,980,280	USD
At 2016-04-30	-84,691,617	USD

Basic weighted-average shares

Time-weighted shares used for basic earnings per share. This denominator differs from shares outstanding at a single reporting date.

Period	Value	Unit	Days
2016-11-01 to 2017-01-31	859,529,933	shares	92
2016-05-01 to 2017-01-31	832,203,911	shares	276
2015-11-01 to 2016-01-31	756,637,143	shares	92
2015-05-01 to 2016-01-31	746,637,216	shares	276

Diluted weighted-average shares

Weighted-average shares used for diluted earnings per share. Potential shares are included under the applicable dilution rules, not simply added to outstanding shares.

Period	Value	Unit	Days
2016-11-01 to 2017-01-31	859,529,933	shares	92
2016-05-01 to 2017-01-31	832,203,911	shares	276
2015-11-01 to 2016-01-31	756,637,143	shares	92
2015-05-01 to 2016-01-31	746,637,216	shares	276

Share-based compensation expense

Reported noncash expense for share-based payment arrangements. Noncash treatment does not mean the awards have no economic cost to shareholders.

Period	Value	Unit	Days
2016-05-01 to 2017-01-31	191,680	USD	276
2015-05-01 to 2016-01-31	309,240	USD	276

Operating income or loss

Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.

Period	Value	Unit	Days
2016-11-01 to 2017-01-31	-1,282,015	USD	92
2016-05-01 to 2017-01-31	-3,287,607	USD	276
2015-11-01 to 2016-01-31	-1,792,151	USD	92
2015-05-01 to 2016-01-31	-4,942,283	USD	276

Current assets

Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.

Period	Value	Unit	Days
At 2017-01-31	2,485,951	USD
At 2016-04-30	2,030,851	USD

Interest expense

Borrowing costs recognized as interest expense. This is distinct from cash interest paid and may not include every capitalized borrowing cost.

Period	Value	Unit	Days
2016-11-01 to 2017-01-31	131	USD	92
2016-05-01 to 2017-01-31	1,056	USD	276
2015-11-01 to 2016-01-31	126	USD	92
2015-05-01 to 2016-01-31	952	USD	276

Current liabilities

Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.

Period	Value	Unit	Days
At 2017-01-31	578,267	USD
At 2016-04-30	637,639	USD

Current accounts payable

Current amounts owed to suppliers for goods and services received. This is one component of current liabilities, not all accrued obligations.

Period	Value	Unit	Days
At 2017-01-31	435,000	USD
At 2016-04-30	336,009	USD

Operating expenses

Recurring operating costs under this accounting concept, generally excluding production costs included in cost of sales. Check filing presentation before combining expense subtotals.

Period	Value	Unit	Days
2016-11-01 to 2017-01-31	1,282,015	USD	92
2016-05-01 to 2017-01-31	3,287,607	USD	276
2015-11-01 to 2016-01-31	1,792,151	USD	92
2015-05-01 to 2016-01-31	4,942,283	USD	276

Gross profit

Revenue less the costs directly attributed to the goods or services sold. It precedes other operating expenses and is not net income.

Period	Unit	Days
2016-11-01 to 2017-01-31	USD	92
2016-05-01 to 2017-01-31	USD	276
2015-11-01 to 2016-01-31	USD	92
2015-05-01 to 2016-01-31	USD	276

Cost of revenue

Costs attributed to goods produced and sold and services provided during the period. This is not the sum of every operating expense.

Period	Unit	Days
2016-11-01 to 2017-01-31	USD	92
2016-05-01 to 2017-01-31	USD	276
2015-11-01 to 2016-01-31	USD	92
2015-05-01 to 2016-01-31	USD	276

Research and development expense

Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.

Period	Value	Unit	Days
2016-11-01 to 2017-01-31	579,717	USD	92
2016-05-01 to 2017-01-31	1,008,489	USD	276
2015-11-01 to 2016-01-31	573,978	USD	92
2015-05-01 to 2016-01-31	1,169,367	USD	276

Common shares outstanding

Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.

Period	Value	Unit	Days
At 2017-01-31	872,237,909	shares
At 2016-04-30	781,233,338	shares

Additional paid-in capital

Capital contributed above par value under this concept. It records historical contributions, not the current value of the equity or cash on hand.

Period	Value	Unit	Days
At 2017-01-31	94,927,788	USD
At 2016-04-30	91,135,370	USD

Accumulated other comprehensive income or loss

Cumulative other comprehensive items after tax, such as translation and unrealized hedging or securities effects. These amounts have not passed through net income.

Period	Value	Unit	Days
At 2017-01-31	1,944	USD
At 2016-04-30	806	USD

Other noncurrent assets

Noncurrent assets the filer does not present separately. The composition differs by filer and is described only in the filing.

Period	Value	Unit	Days
At 2017-01-31	7,372	USD
At 2016-04-30	7,854	USD

Accrued current liabilities

Current obligations accrued for goods and services received but not yet invoiced or paid. This is one component of current liabilities, not all short-term obligations.

Period	Value	Unit	Days
At 2017-01-31	143,267	USD
At 2016-04-30	151,630	USD

Prepaid expenses and other current assets

Prepayments and other current assets grouped under this concept. The balance is not cash and its composition differs by filer.

Period	Value	Unit	Days
At 2017-01-31	21,680	USD
At 2016-04-30	110,026	USD

Comprehensive income or loss

Net income plus other comprehensive income after tax. It includes unrealized items that net income excludes and is not a cash measure.

Period	Value	Unit	Days
2016-11-01 to 2017-01-31	-1,281,846	USD	92
2016-05-01 to 2017-01-31	-3,286,719	USD	276
2015-11-01 to 2016-01-31	-1,790,895	USD	92
2015-05-01 to 2016-01-31	-4,939,931	USD	276

General and administrative expense

General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.

Period	Value	Unit	Days
2016-11-01 to 2017-01-31	151,833	USD	92
2016-05-01 to 2017-01-31	569,409	USD	276
2015-11-01 to 2016-01-31	570,989	USD	92
2015-05-01 to 2016-01-31	2,067,592	USD	276

Other nonoperating income or expense

Other income or expense outside operations under this concept. The composition is filer-specific and can include one-time items.

Period	Value	Unit	Days
2016-11-01 to 2017-01-31	-131	USD	92
2016-05-01 to 2017-01-31	-1,056	USD	276
2015-11-01 to 2016-01-31	1,054	USD	92
2015-05-01 to 2016-01-31	563	USD	276

Proceeds from issuing common stock

Cash received from issuing common stock during the period. It is gross of costs only where the filer reports it so, and it does not include noncash issuances.

Period	Value	Unit	Days
2016-05-01 to 2017-01-31	3,080,883	USD	276
2015-05-01 to 2016-01-31	3,291,622	USD	276

Change in accounts payable

The cash flow adjustment for the change in payables during the period. A positive value under this concept means payables grew and added to operating cash flow.

Period	Value	Unit	Days
2016-05-01 to 2017-01-31	98,991	USD	276
2015-05-01 to 2016-01-31	200,623	USD	276

Inspect the source

Entity: PHARMACYTE BIOTECH, INC. / CIK 0001157075
Captured: 2026-09-20T07:42:36.237Z
SEC response SHA-256: 8f9ad1662a11f3cb167c6975b558c6cce5e582ddebd7699a946a7cffe2a40413

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

Read the published dataset with Python

import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0001157075.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))